Days Post Inoculation (DPI) | |||||||||
---|---|---|---|---|---|---|---|---|---|
Treatment | Assay | 0 | 7 | 10 | 14 | 17 | 21 | 24 | 28 |
Control | wv-ELISAA | 0 (0/2)1 | 0 (0/2) | 0 (0/2) | 0 (0/2) | 0 (0/2) | 0 (0/2) | 0 (0/2) | 0 (0/2) |
IFAB | 0 (0/2) | 0 (0/2) | 0 (0/2) | 0 (0/2) | 0 (0/2) | 0 (0/2) | 0 (0/2) | 0 (0/2) | |
SVNC | 0 (0/2) | 0 (0/2) | 0 (0/2) | 0 (0/2) | 0 (0/2) | 0 (0/2) | 0 (0/2) | 0 (0/2) | |
HPIV-1 | wv-ELISAA | 0 (0/3) | 0 (0/3) | 0 (0/3) | 0 (0/3) | 0 (0/3) | 0 (0/3) | 0 (0/3) | 0 (0/3) |
IFAB | 0 (0/3) | 0 (0/3) | 0 (0/3) | 0 (0/3) | 0 (0/3) | 0 (0/3) | 0 (0/3) | 0 (0/3) | |
SVNC | 0 (0/3) | 0 (0/3) | 0 (0/3) | 0 (0/3) | 0 (0/3) | 0 (0/3) | 0 (0/3) | 0 (0/3) | |
IA17 | wv-ELISAA | 0 (0/3) | 0 (0/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) |
IFAB | 0 (0/3) | 0 (0/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) | |
SVNC | 0 (0/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) | |
MN16 | wv-ELISAA | 0 (0/3) | 0 (0/3) | 33 (1/3) | 67 (2/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) |
IFAB | 0 (0/3) | 0 (0/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) | |
SVNC | 0 (0/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) | 100 (3/3) |